Therapeutic Monoclonal Antibodies - by Zhiqiang An (Hardcover)

Book Synopsis

• 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies.
• First book to address the discovery and development of antibody therapeutics in their entirety.
• Most chapters contain experimental data to illustrate the principles described in them.
• Authors provide detailed methodologies that readers can take away with them and use in their own laboratories.

From the Back Cover

BRINGS TOGETHER THE STATE OF KNOWLEDGE AND PRACTICE IN THERAPEUTIC MONOCLONAL ANTIBODIES

The first therapeutic antibody, murine-derived Muromonab OKT3^(R), was approved by the FDA in 1986 to treat acute organ rejection. Since then, monoclonal antibody therapeutics have played an increasing role in combating human diseases. To discover the state of the science and where this burgeoning field is heading, readers should turn to this 35-chapter work. It is the first book that draws together all the latest findings, tools, and practices that span the entire process of discovery, development, and clinical application of therapeutic monoclonal antibodies.

Therapeutic Monoclonal Antibodies reviews:

• Basic antibody biology and antibody sources
• Antibody engineering
• Physiology and in vivo biology
• Antibody production and delivery
• Antibody therapeutic targets
• Therapeutic monoclonal antibodies in clinical use and in clinical trial
• Biogenerics/biosimilars

Chapters are written by one or more leading practitioners with hands-on experience in the area. The authors have provided not only theories but also methodologies that readers can use in their own laboratories. Moreover, experimental data is offered in most chapters to illustrate key principles.

Therapeutic Monoclonal Antibodies is recommended for biotechnologists, immunologists, medicinal and pharmaceutical chemists, bioengineers, bioprocess technologists, biochemists, and students. It will help them advance their own basic and clinical research by taking advantage of the latest findings in the discovery, development, and clinical application of therapeutic monoclonal antibodies.

About the Author

ZHIQIANG AN, PHD, is the Chief Scientific Officer of Epitomics, Inc., in Burlingame, California. Previously, he was Director of Biologics Research at Merck Research Laboratories, West Point, Pennsylvania. Dr. An started his biotech/pharmaceutical career at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. He received a doctor of philosophy degree from the University of Kentucky, Lexington, followed by postdoctoral training at the University of Wisconsin-Madison.